Akvano/calcipotriol: Phase I/IIa data

A double-blind Phase I/IIa trial in 24 patients with psoriasis vulgaris showed that 10 topical applications of Akvano/calcipotriol over 12 days met the primary endpoint of reducing psoriatic infiltrat...